{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T15:02:53Z","timestamp":1791385373590,"version":"4.3.3"},"reference-count":106,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2009,4,1]],"date-time":"2009-04-01T00:00:00Z","timestamp":1238544000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2009,4,1]],"date-time":"2009-04-01T00:00:00Z","timestamp":1238544000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Hormones"],"published-print":{"date-parts":[[2009,4]]},"DOI":"10.14310\/horm.2002.1226","type":"journal-article","created":{"date-parts":[[2014,1,29]],"date-time":"2014-01-29T13:38:15Z","timestamp":1391002695000},"page":"96-110","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":258,"title":["Bisphosphonate-associated adverse events"],"prefix":"10.1007","volume":"8","author":[{"given":"Peter D.","family":"Papapetrou","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2009,4,1]]},"reference":[{"key":"8020096_CR1","doi-asserted-by":"publisher","first-page":"6222s","DOI":"10.1158\/1078-0432.CCR-06-0843","volume":"12","author":"AJ Roelofs","year":"2006","unstructured":"Roelofs AJ, Thompson K, Gordon S, Rogers MJ, 2006 Molecular mechanisms of action of bisphosphonates: current status. Clin Cancer Res 12: 6222s\u20136230s.","journal-title":"Clin Cancer Res"},{"key":"8020096_CR2","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1056\/NEJMoa0802633","volume":"360","author":"RS Weinstein","year":"2009","unstructured":"Weinstein RS, Roberston PK, Manolagas SC, 2009 Giant osteoclast formation and long-term oral bisphosphonate therapy. N Engl J Med 360: 53\u201362.","journal-title":"N Engl J Med"},{"key":"8020096_CR3","doi-asserted-by":"publisher","first-page":"897","DOI":"10.1093\/annonc\/mdj105","volume":"17","author":"T Tanvetyanon","year":"2006","unstructured":"Tanvetyanon T, Stiff PJ, 2006 Management of the adverse effects associated with intravenous disphosphonates. Ann Oncol 17: 897\u2013907.","journal-title":"Ann Oncol"},{"key":"8020096_CR4","doi-asserted-by":"publisher","first-page":"1016","DOI":"10.1056\/NEJM199610033351403","volume":"335","author":"PC de Groen","year":"1996","unstructured":"de Groen PC, Lubbe DF, Hirsch LJ, et al, 1996 Esophagitis associated with the use of alendronate. N Engl J Med 335: 1016\u20131021.","journal-title":"N Engl J Med"},{"key":"8020096_CR5","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1001\/archinte.160.4.517","volume":"160","author":"DC Bauer","year":"2000","unstructured":"Bauer DC, Black D, Ensrud K, et al, 2000 Upper gastrointestinal tract safety profile of alendronate. The fracture intervention trial. Arch Intern Med 160: 517\u2013525.","journal-title":"Arch Intern Med"},{"key":"8020096_CR6","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1111\/j.1365-2036.2005.02378.x","volume":"21","author":"B Cryer","year":"2005","unstructured":"Cryer B, Miller P, Petruschke RA, Chen E, Geba GP, De Papp AE, 2005 Upper gastrointestinal tolerability of once weekly alendronate 70 mg with concomitant non-steroidal anti-inflammatory drug use. Aliment Pharmacol Ther 21: 599\u2013607.","journal-title":"Aliment Pharmacol Ther"},{"key":"8020096_CR7","doi-asserted-by":"publisher","first-page":"1044","DOI":"10.4065\/77.10.1044","volume":"77","author":"S Greenspan","year":"2002","unstructured":"Greenspan S, Field-Munves E, Tonino R, et al, 2002 Tolerability of once-weekly alendromate in patients with osteoporosis: a randomized, double-blind, placebo-controlled study. Mayo Clin Proc 77: 1044\u20131052.","journal-title":"Mayo Clin Proc"},{"key":"8020096_CR8","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1185\/030079904125003548","volume":"20","author":"JA Eisman","year":"2004","unstructured":"Eisman JA, Rizzoli R, Roman-Ivorra J, et al, 2004 Upper gastrointestinal and overall tolerability of alendronate once weekly in patients with osteoporosis: results of a randomized, double-blind, placebo-contolled study. Curr Med Res Opin 20: 699\u2013705.","journal-title":"Curr Med Res Opin"},{"key":"8020096_CR9","doi-asserted-by":"publisher","first-page":"1031","DOI":"10.4065\/77.10.1031","volume":"77","author":"B Cryer","year":"2002","unstructured":"Cryer B, Bauer DC, 2002 Oral bisphosphonates and upper gastrointestinal tract problems: what is the evidence? Mayo Clin Proc 77: 1031\u20131043.","journal-title":"Mayo Clin Proc"},{"key":"8020096_CR10","doi-asserted-by":"publisher","first-page":"1133","DOI":"10.2165\/00002018-200629120-00005","volume":"29","author":"RS Bobba","year":"2006","unstructured":"Bobba RS, Beattie K, Parkinson B, Kumbhare D, Adachi JD, 2006 Tolerability of different dosing regimens of bisphosphonates for the treatment of osteoporosis and malignant bone disease. Drug Saf 29: 1133\u20131152.","journal-title":"Drug Saf"},{"key":"8020096_CR11","doi-asserted-by":"publisher","first-page":"1448","DOI":"10.1016\/S0016-5085(97)70025-8","volume":"112","author":"GR Locke 3rd","year":"1997","unstructured":"Locke GR 3rd, Talley NJ, Fett SL, Zinsmeister AR, Melton LJ 3rd, 1997 Prevalence and clinical spectrum of gastroesophageal reflux: a population-based study in Olmsted County, Minnesota. Gastroenterology 112: 1448\u20131456.","journal-title":"Gastroenterology"},{"key":"8020096_CR12","first-page":"32","volume-title":"Bisphosphonates in bone disease. From the laboratory to the patient","author":"H Fleisch","year":"2000","unstructured":"Fleisch H, 2000 Bisphosphonates in bone disease. From the laboratory to the patient. Academic Press. San Diego, CA, pp, 32, 168."},{"key":"8020096_CR13","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1016\/S0140-6736(83)91465-4","volume":"1","author":"HM Bounameaux","year":"1983","unstructured":"Bounameaux HM, Schifferli J, Montani JP, Jung A, Chatelanat F, 1983 Renal failure associated with intravenous bisphosphonates. Lancet 1: 471.","journal-title":"Lancet"},{"key":"8020096_CR14","doi-asserted-by":"publisher","first-page":"1735","DOI":"10.1002\/cncr.11701","volume":"98","author":"LS Rosen","year":"2003","unstructured":"Rosen LS, Gordon D, Kaminski M, et al, 2003 Long-term efficacy and safety of zoledronic acid compared with pamidronate disodium in the treatment of skeletal complications in patients with advanced multiple myeloma or breast carcinoma: a randomized, double-blind, multicenter, comparative trial. Cancer 98: 1735\u20131744.","journal-title":"Cancer"},{"key":"8020096_CR15","doi-asserted-by":"publisher","first-page":"1676","DOI":"10.1056\/NEJMra022308","volume":"349","author":"JT Chang","year":"2003","unstructured":"Chang JT, Green L, Beitz J, 2003 Renal failure with the use of zoledronic acid. N Engl J Med 349: 1676\u20131679.","journal-title":"N Engl J Med"},{"key":"8020096_CR16","first-page":"534","volume":"29","author":"R Bergner","year":"2006","unstructured":"Bergner R, Diel IJ, Henrich D, Hoffmann M, Uppenkamp M, 2006 Differences in nephrotoxicity of intravenous bisphosphonates for the treatment of malignancy-related bone disease. Onkologie 29: 534\u2013540.","journal-title":"Onkologie"},{"key":"8020096_CR17","doi-asserted-by":"publisher","first-page":"1385","DOI":"10.1038\/ki.2008.356","volume":"74","author":"MA Perazella","year":"2008","unstructured":"Perazella MA, Markowitz GS, 2008 Bisphosphonate nephrotoxicity. Kidney Int 74: 1385\u20131393.","journal-title":"Kidney Int"},{"key":"8020096_CR18","doi-asserted-by":"publisher","first-page":"306","DOI":"10.1634\/theoncologist.10-5-306","volume":"10","author":"J Balla","year":"2005","unstructured":"Balla J, 2005 The issue of renal safety of zoledronic acid from a nephrologist\u2019s point of view. Oncologist 10: 306\u2013308.","journal-title":"Oncologist"},{"key":"8020096_CR19","doi-asserted-by":"publisher","first-page":"4042","DOI":"10.1200\/JCO.2003.08.017","volume":"21","author":"BE Hillner","year":"2003","unstructured":"Hillner BE, Ingle JN, Chlebowski RT, et al, 2003 American society of clinical oncology 2003 update on the role of bisphosphonates and bone health issues in women with breast cancer. J Clin Oncol 21: 4042\u20134057.","journal-title":"J Clin Oncol"},{"key":"8020096_CR20","doi-asserted-by":"publisher","first-page":"77","DOI":"10.3816\/SCT.2006.n.002","volume":"3","author":"JJ Body","year":"2006","unstructured":"Body JJ, 2006 The risk of cumulative renal effects of intravenous bisphosphonates. Support Cancer Ther 3: 77\u201383.","journal-title":"Support Cancer Ther"},{"key":"8020096_CR21","doi-asserted-by":"publisher","first-page":"570","DOI":"10.1007\/s00198-003-1435-y","volume":"14","author":"S Klawansky","year":"2003","unstructured":"Klawansky S, Komaroff E, Cavanaugh PF, et al, 2003 Relationship between age, renal function and bone mineral density in the US population. Osteoporos Int 14: 570\u2013576.","journal-title":"Osteoporos Int"},{"key":"8020096_CR22","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1359\/jbmr.061014","volume":"22","author":"SK Jassal","year":"2007","unstructured":"Jassal SK, von Muhlen D, Barrett-Connor E, 2007 Measures of renal function, BMD, bone loss, and osteoporotic fracture in older adults: the Rancho Bernardo Study. J Bone Min Res 22: 203\u2013210.","journal-title":"J Bone Min Res"},{"key":"8020096_CR23","doi-asserted-by":"publisher","first-page":"2105","DOI":"10.1359\/JBMR.050817","volume":"20","author":"PD Miller","year":"2005","unstructured":"Miller PD, Roux C, Boonen S, Barton IP, Dunlap LE, Burgio DE, 2005 Safety and efficacy of risedronate in patients with age-related reduced renal function as estimated by the Cockcroft and Gaukt method: a pooled analysis of nine clinical trials. J Bone Min Res 20: 2105\u20132115.","journal-title":"J Bone Min Res"},{"key":"8020096_CR24","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1007\/s10157-008-0078-x","volume":"13","author":"N Miura","year":"2009","unstructured":"Miura N, Mizuno N, Aoyama R, 2009 Massive proteinuria and acute renal failure after oral bisphosphonate (alendronate) administration in a patient with segmental glomerulosclerosis. Clin Exp Nephrol 13: 85\u201388.","journal-title":"Clin Exp Nephrol"},{"key":"8020096_CR25","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1016\/S0002-9394(02)01840-8","volume":"135","author":"FW Fraunfelder","year":"2003","unstructured":"Fraunfelder FW, Fraunfelder FT, Jensvold B, 2003 Scleritis and other ocular side effects associated with pamidronate disodium. Am J Ophthalmol 135: 219\u2013222.","journal-title":"Am J Ophthalmol"},{"key":"8020096_CR26","doi-asserted-by":"publisher","first-page":"889","DOI":"10.1097\/IAE.0b013e31816576ef","volume":"28","author":"DD French","year":"2008","unstructured":"French DD, Margo CE, 2008 Postmarketing surveillance of uveitis and scleritis with bisphosphonates among a national veteran cohort. Retina 28: 889\u2013893.","journal-title":"Retina"},{"key":"8020096_CR27","doi-asserted-by":"publisher","first-page":"145","DOI":"10.3816\/CLM.2006.n.053","volume":"7","author":"D Benderson","year":"2006","unstructured":"Benderson D, Karakunnel, Kathuria S, Badros A, 2006 Scleritis complicating zoledronic acid infusion. Clin Lymphoma Myeloma 7: 145\u2013147.","journal-title":"Clin Lymphoma Myeloma"},{"key":"8020096_CR28","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1186\/1471-2407-5-156","volume":"5","author":"NS El Saghir","year":"2005","unstructured":"El Saghir NS, Otrock ZK, Bleik JH, 2005 Unilateral anterior uveitis complicating zoledronic acid therapy in breast cancer. BMC Cancer 5: 156.","journal-title":"BMC Cancer"},{"key":"8020096_CR29","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1007\/s12032-007-9006-2","volume":"25","author":"S Kilickap","year":"2008","unstructured":"Kilickap S, Ozdamar Y, Altundag MK, Dizdar O, 2008 A case report: zoledronic acid -induced uveitis. Med Oncol 25: 238\u2013240.","journal-title":"Med Oncol"},{"key":"8020096_CR30","doi-asserted-by":"publisher","first-page":"733","DOI":"10.1097\/01.SMJ.0000152753.80490.9F","volume":"98","author":"S Leung","year":"2005","unstructured":"Leung S, Ashar BH, Miller RG, 2005 Bisphosphonate-assocoated scleritis: a case report and review. South Med J 98: 733\u2013735.","journal-title":"South Med J"},{"key":"8020096_CR31","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1080\/09273940802056281","volume":"16","author":"KF Tabbara","year":"2008","unstructured":"Tabbara KF, 2008 Nodular scleritis following alendronate therapy. Ocul Immunol Inflamm 16: 99\u2013101.","journal-title":"Ocul Immunol Inflamm"},{"key":"8020096_CR32","first-page":"837","volume":"117","author":"JN Mbekeani","year":"1999","unstructured":"Mbekeani JN, Slamivits TL, Schwartz BH, Sauer HL, 1999 Ocular inflammation associated with alendronate therapy. Arch Ophthalmol 117: 837\u2013838.","journal-title":"Arch Ophthalmol"},{"key":"8020096_CR33","doi-asserted-by":"publisher","first-page":"1443","DOI":"10.1136\/bjo.86.12.1443","volume":"86","author":"AR Malik","year":"2002","unstructured":"Malik AR, Campbell SH, Toma NMG, 2002 Bilateral acute anterior uveitis after alendronate. Br J Ophthalmol 86: 1443.","journal-title":"Br J Ophthalmol"},{"key":"8020096_CR34","doi-asserted-by":"publisher","first-page":"378","DOI":"10.1136\/ard.62.4.378","volume":"62","author":"P Fietta","year":"2003","unstructured":"Fietta P, Manganelli P, Lodigiani L, 2003 Clodronate induced uveitis. Ann Rheum Dis 62: 378.","journal-title":"Ann Rheum Dis"},{"key":"8020096_CR35","doi-asserted-by":"publisher","first-page":"151","DOI":"10.2165\/00002018-200629020-00005","volume":"29","author":"B Aurich-Barrera","year":"2006","unstructured":"Aurich-Barrera B, Wilton L, Harris S, Shakir SW, 2006 Ophthalmological events in patients receiving risedronate: summary of information gained through follow-up in a prescription-event monitoring study in England. Drug Safety 29: 151\u2013160.","journal-title":"Drug Safety"},{"key":"8020096_CR36","doi-asserted-by":"publisher","first-page":"326","DOI":"10.1007\/BF02556671","volume":"41","author":"S Adami","year":"1987","unstructured":"Adami S, Bhalla AK, Dorizzi R, 1987 The acute-phase response after bisphosphonate administration. Calcif Tissue Int 41: 326\u2013331.","journal-title":"Calcif Tissue Int"},{"key":"8020096_CR37","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1177\/1078155207080806","volume":"13","author":"K Olson","year":"2007","unstructured":"Olson K, Van Poznak C, 2007 Significance and impact of bisphosphonate-induced acute phase responses. J Oncol Pharm Practice 13: 223\u2013229.","journal-title":"J Oncol Pharm Practice"},{"key":"8020096_CR38","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1093\/annonc\/mdl298","volume":"18","author":"D Santini","year":"2007","unstructured":"Santini D, Vincenzi B, Caraglia M, Tonini G, 2007 A hitherto unreported high incidence of zoledronic acid-induced acute phase reaction in patients with cancer treatment-induced bone loss. Ann Oncol 18: 201\u2013202.","journal-title":"Ann Oncol"},{"key":"8020096_CR39","doi-asserted-by":"publisher","first-page":"1315","DOI":"10.1359\/JBMR.050313","volume":"20","author":"PD Miller","year":"2005","unstructured":"Miller PD, McClung MR, Macovei L, et al, 2005 Monthly oral ibandronate therapy in postmenopausal osteoporosis: 1-year results from the MOBILE study. J Bone Min Res 20: 1315\u20131322.","journal-title":"J Bone Min Res"},{"key":"8020096_CR40","doi-asserted-by":"publisher","first-page":"956","DOI":"10.1002\/jbmr.5650100617","volume":"10","author":"DH Schweitzer","year":"1995","unstructured":"Schweitzer DH, Oostendorp-vande Ruit M, van der Pluijm G, Lowik CWGM, Papapoulos SE, 1995 Interleukin-6 and the acute phase response during treatment of patients with Paget\u2019s disease with the nitrogen-containing bisphosphonate dimethylamonohydroxypoproylidine bisphosphonate. J Bone Min Res 10: 956\u2013962.","journal-title":"J Bone Min Res"},{"key":"8020096_CR41","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1111\/j.1365-2249.2005.02665.x","volume":"139","author":"RE Hewitt","year":"2005","unstructured":"Hewitt RE, Lissina A, Green AE, Slay ES, Price DA, Sewell AK, 2005 The bisphosphonate acute phase response: rapid and copious production of proinflammatory cytokines by peripheral blood \u03b3\u03b4 T cells in response to aminobisphosphonates is inhibited by statins. Clin Exp Immunol 139: 101\u2013111.","journal-title":"Clin Exp Immunol"},{"key":"8020096_CR42","doi-asserted-by":"publisher","first-page":"334","DOI":"10.1359\/jbmr.081016","volume":"24","author":"T Srivastava","year":"2009","unstructured":"Srivastava T, Haney CJ, Alon US, 2009 Atorvastatin may have no effect on acute phase reaction in children following intravenous bisphosphonate infusion. J Bone Min Res 24: 334\u2013337.","journal-title":"J Bone Min Res"},{"key":"8020096_CR43","first-page":"1399","volume":"76","author":"ST Harris","year":"1993","unstructured":"Harris ST, Gertz BJ, Genant HK, et al, 1993 The effect of short term treatment with alendronate on vertebral density and biochemical markers of bone remodeling in early postmenopausal women J Clin Endocrinol Metab 76: 1399\u20131406.","journal-title":"J Clin Endocrinol Metab"},{"key":"8020096_CR44","doi-asserted-by":"publisher","first-page":"635","DOI":"10.1111\/j.1445-5994.2007.01580.x","volume":"38","author":"S Chennuru","year":"2008","unstructured":"Chennuru S, Koduri J, Bauman MA, 2008 Risk factors for symtomatic hypocalcemia complicating treatment with zoledronic acid. Intern Med J 38: 635\u2013637.","journal-title":"Intern Med J"},{"key":"8020096_CR45","doi-asserted-by":"publisher","first-page":"329","DOI":"10.7326\/0003-4819-130-4-199902160-00008","volume":"130","author":"DH Schussheim","year":"1999","unstructured":"Schussheim DH, Jacobs TP, Silverberg SJ, 1999 Hypocalcemia associated with alendronate. Ann Intern Med 130: 329.","journal-title":"Ann Intern Med"},{"key":"8020096_CR46","doi-asserted-by":"publisher","first-page":"48","DOI":"10.4158\/EP.12.1.48","volume":"12","author":"NM Maalouf","year":"2006","unstructured":"Maalouf NM, Heller HJ, Odvina CV, Kim PJ, Sakhaee K, 2006 Bisphosphonate-induced hypocalcemia: report of 3 cases and review of literature. Endocr pract 12: 48\u201353.","journal-title":"Endocr pract"},{"key":"8020096_CR47","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1177\/000313480507101017","volume":"71","author":"BK Richmond","year":"2005","unstructured":"Richmond BK, 2005 Profound refractory hypocalcemia after thyroidectomy in a patient receiving chronic oral bisphosphonate therapy. Am Surg 71: 872\u2013873.","journal-title":"Am Surg"},{"key":"8020096_CR48","doi-asserted-by":"publisher","first-page":"615","DOI":"10.1177\/014107680209501212","volume":"95","author":"RJ Macisaac","year":"2002","unstructured":"Macisaac RJ, Seeman E, Herums G, 2002 Seizures after alendronate. J Royal Soc Med 95: 615\u2013616.","journal-title":"J Royal Soc Med"},{"key":"8020096_CR49","doi-asserted-by":"publisher","first-page":"726","DOI":"10.1111\/j.1445-5994.2005.00949.x","volume":"35","author":"D Henley","year":"2005","unstructured":"Henley D, Kaye J, Walsh J, Cull G, 2005 Symptomatic hypocalcemia and renal impairment associated with bisphosphonate treatment in patients with multiple myeloma. Intern Med J 35: 726\u2013728.","journal-title":"Intern Med J"},{"key":"8020096_CR50","doi-asserted-by":"publisher","first-page":"1854","DOI":"10.1093\/annonc\/mdl181","volume":"17","author":"A Berruti","year":"2006","unstructured":"Berruti A, Tucci M, Generali D, et al, 2006 Management of the side-effects of intravenous bisphosphonates: targeting the serum parathyroid hormone elevation. Ann Oncol 17: 1854\u20131855.","journal-title":"Ann Oncol"},{"key":"8020096_CR51","unstructured":"http:\/\/www.fda.gov\/cder\/drug\/infopage\/bisphosphonates\/default.htm"},{"key":"8020096_CR52","doi-asserted-by":"publisher","first-page":"346","DOI":"10.1001\/archinte.165.12.1363","volume":"165","author":"DK Wysowski","year":"2005","unstructured":"Wysowski DK, Chang JT, 2005 Alendronate and risedronate: reports of severe bone, joint, and muscle pain. Arch Intern Med 165: 346\u2013347.","journal-title":"Arch Intern Med"},{"key":"8020096_CR53","first-page":"144","volume":"7","author":"O Bock","year":"2007","unstructured":"Bock O, Boerst H, Thomasius FE, et al, 2007 Common musculoskeletal adverse effects of oral treatment with once weekly alendronate and risedronate in patients with osteoporosis and ways for their prevention. J Musculoskelet Neuronal Interact 7: 144\u2013148.","journal-title":"J Musculoskelet Neuronal Interact"},{"key":"8020096_CR54","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1136\/bmj.330.7482.74","volume":"330","author":"D Gwynne Jones","year":"2005","unstructured":"Gwynne Jones D, Savage R, Highton J, 2005 Synovitis induced by alendronic acid can present as acute carpal tunnel syndrome. BMJ 330: 74.","journal-title":"BMJ"},{"key":"8020096_CR55","first-page":"537","volume":"35","author":"DP Gwynne Jones","year":"2008","unstructured":"Gwynne Jones DP, Savage RL, Highton J, 2008 Alendronate-induced synovitis. J Rheumatol 35: 537\u2013538.","journal-title":"J Rheumatol"},{"key":"8020096_CR56","first-page":"829","volume":"31","author":"JC Gerster","year":"2004","unstructured":"Gerster JC, 2004 Acute polyarthritis related to once-weekly alendronate in a woman with osteoporosis. J Rheumatol 31: 829\u2013830.","journal-title":"J Rheumatol"},{"key":"8020096_CR57","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1136\/bmj.329.7458.156","volume":"329","author":"G de Torrent\u00e9 da la Jara","year":"2004","unstructured":"de Torrent\u00e9 da la Jara G, P\u00e9coud A, Favrat B, 2004 Musculoskeletal pain in female asylum seekers and hypovitaminosis D3. BMJ 329: 156\u2013157.","journal-title":"BMJ"},{"key":"8020096_CR58","first-page":"411","volume-title":"The Parathyroids, Basic and Clinical Concepts","author":"IA Nakchbandi","year":"2001","unstructured":"Nakchbandi IA, Grey A, Masiukewicz U, Mitnick M, Insogna K 2001 Cytokines in primary hyperparathyroidism. In: Bilezikian JP, Marcus R, Levine M (eds). The Parathyroids, Basic and Clinical Concepts. Academic Press, San Diego, CA; pp, 411\u2013421."},{"key":"8020096_CR59","doi-asserted-by":"publisher","first-page":"1166","DOI":"10.1016\/S1470-2045(08)70305-X","volume":"9","author":"BJ Edwards","year":"2008","unstructured":"Edwards BJ, Gounder M, McKoy JM, 2008 Pharmaco-vigilance and reporting oversight in US FDA fast-track process: bisphosphonates and osteonecrosis of the jaw. Lancet Oncol 9: 1166\u20131172.","journal-title":"Lancet Oncol"},{"key":"8020096_CR60","doi-asserted-by":"publisher","first-page":"1238","DOI":"10.1016\/S0278-2391(03)00720-1","volume":"61","author":"RE Marx","year":"2003","unstructured":"Marx RE, 2003 Pamidronate (Aredia) and Zoledronate (Zometa) induced avascular necrosis of the jaws: a growing epidemic. J Oral Maxillofac Surg 61: 1238\u20131239.","journal-title":"J Oral Maxillofac Surg"},{"key":"8020096_CR61","doi-asserted-by":"publisher","first-page":"527","DOI":"10.1016\/j.joms.2004.02.004","volume":"62","author":"SL Ruggiero","year":"2004","unstructured":"Ruggiero SL, Mehrotra B, Rosenberg TJ, Engroff SL, 2004 Osteonecrosis of the jaws associated with the use of bisphosphonates: a review of 63 cases. J Oral Maxillofac Surg 62: 527\u2013534.","journal-title":"J Oral Maxillofac Surg"},{"key":"8020096_CR62","doi-asserted-by":"publisher","first-page":"8580","DOI":"10.1200\/JCO.2005.02.8670","volume":"23","author":"A Bamias","year":"2005","unstructured":"Bamias A, Kastritis E, Bamia C, 2005 Osteonecrosis of the jaw in cancer after treatment with bisphosphonates: incidence and risk factors. J Clin Oncol 23: 8580\u20138587.","journal-title":"J Clin Oncol"},{"key":"8020096_CR63","doi-asserted-by":"publisher","first-page":"1479","DOI":"10.1359\/jbmr.0707onj","volume":"22","author":"S Khosla","year":"2007","unstructured":"Khosla S, Burr D, Cauley J, 2007 Bisphosphonate-associated osteonecrosis of the jaw: report of a task force of the American Society for Bone Na Mineral Research. Editorial. J Bone Min Res 22: 1479\u20131491.","journal-title":"Editorial. J Bone Min Res"},{"key":"8020096_CR64","doi-asserted-by":"publisher","first-page":"753","DOI":"10.7326\/0003-4819-144-10-200605160-00009","volume":"144","author":"SB Woo","year":"2006","unstructured":"Woo SB, Hellstein JW, Kalmar JR, 2006 Systematic review: bisphosphonates and osteonecrosis of the jaws. Ann Intern Med 144: 753\u2013761.","journal-title":"Ann Intern Med"},{"key":"8020096_CR65","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1200\/jop.2006.2.1.7","volume":"2","author":"S Ruggiero","year":"2006","unstructured":"Ruggiero S, Gralow J, Marx RE, 2006 Practical guidelines for the prevention, diagnosis, and treatment of osteonecrosis of the jaw in patients with cancer. J Oncol Pract 2: 7\u201314.","journal-title":"J Oncol Pract"},{"key":"8020096_CR66","unstructured":"American Association of Oral and Maxillofacial Surgeons Position Paper on Bisphosphonate-Related Osteonecrosis of the Jaws, September 25, 2006 http:\/\/www. aaoms.org\/docs\/position_papers\/osteonecrosis.pdf."},{"key":"8020096_CR67","doi-asserted-by":"publisher","first-page":"2397","DOI":"10.1016\/j.joms.2007.08.003","volume":"65","author":"RE Marx","year":"2007","unstructured":"Marx RE, Cillo JE Jr, Ulloa JJ, 2007 Oral bisphosphonate-induced osteonecrosis: risk factors, prediction of risk using serum CTX testing, prevention, and treatment. J Oral Maxillofac Surg 65: 2397\u20132410.","journal-title":"J Oral Maxillofac Surg"},{"key":"8020096_CR68","doi-asserted-by":"publisher","first-page":"1548","DOI":"10.1016\/j.clinthera.2007.08.008","volume":"29","author":"M Pazianas","year":"2007","unstructured":"Pazianas M, Miller P, Blumentals WA, Bernal M, Kothawala P, 2007 A review of the literature on osteonecrosis of the jaw in patients with osteoporosis treated with oral bisphosphonates: prevalence, risk factors, and clinical characteristics. Clin Ther 29: 1548\u20131558.","journal-title":"Clin Ther"},{"key":"8020096_CR69","doi-asserted-by":"publisher","first-page":"841","DOI":"10.1016\/j.bone.2008.01.003","volume":"42","author":"R Rizzoli","year":"2008","unstructured":"Rizzoli R, Burlet N, Cahall D, et al, 2008 Osteonecrosis of the jaw and bisphosphonate treatment for osteoporosis. Bone 42: 841\u2013847.","journal-title":"Bone"},{"key":"8020096_CR70","doi-asserted-by":"publisher","first-page":"2356","DOI":"10.1016\/j.joms.2007.11.006","volume":"66","author":"RE Marx","year":"2008","unstructured":"Marx RE, 2008 Uncovering the cause of \u201cphossy jaw\u201d circa 1858 to 1906: oral and maxillofacial surgery closed case file-case closed. J Oral Maxillofac Surg 66: 2356\u20132363.","journal-title":"J Oral Maxillofac Surg"},{"key":"8020096_CR71","doi-asserted-by":"publisher","first-page":"1336","DOI":"10.1093\/annonc\/mdl045","volume":"17","author":"M Ardine","year":"2006","unstructured":"Ardine M, Generali D, Donadio M, 2006 Could the long-term persistence of low serum calcium levels and high serum parathyroid hormone levels during bisphosphonate treatment predispose metastatic breast cancer patients to undergo osteonecrosis of the jaw? Ann Oncol 17: 1336\u20131337.","journal-title":"Ann Oncol"},{"key":"8020096_CR72","doi-asserted-by":"publisher","first-page":"3439","DOI":"10.1210\/jc.2005-2282","volume":"91","author":"AD Padbury Jr","year":"2006","unstructured":"Padbury AD Jr, T\u00f6z\u00fcm TF, Taba M Jr, et al, 2006 The impact of primary hyperparathyroidism on the oral cavity. J Clin Endocrinol Metab 91: 3439\u20133445.","journal-title":"J Clin Endocrinol Metab"},{"key":"8020096_CR73","doi-asserted-by":"publisher","first-page":"1139","DOI":"10.3174\/ajnr.A0518","volume":"28","author":"PM Phal","year":"2007","unstructured":"Phal PM, Myall RWT, Assael LA, Weissman JL, 2007 Imaging findings of bisphosphonate-associated osteonecrosis of the jaw. Am J Neuroradiol 28: 1139\u20131145.","journal-title":"Am J Neuroradiol"},{"key":"8020096_CR74","doi-asserted-by":"publisher","first-page":"1809","DOI":"10.1056\/NEJMoa067312","volume":"356","author":"DM Black","year":"2007","unstructured":"Black DM, Delmas PD, Eastell R, et al, 2007 Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis. N Engl J Med 356: 1809\u20131822.","journal-title":"N Engl J Med"},{"key":"8020096_CR75","doi-asserted-by":"publisher","first-page":"2077","DOI":"10.1001\/jama.280.24.2077","volume":"280","author":"SR Cummings","year":"1998","unstructured":"Cummings SR, Balck DM, Thompson DE, et al, 1998 Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: results from the Fracture Intervention Trial. JAMA 280: 2077\u20132082.","journal-title":"JAMA"},{"key":"8020096_CR76","doi-asserted-by":"publisher","first-page":"1895","DOI":"10.1056\/NEJMc076132","volume":"356","author":"SR Cummings","year":"2007","unstructured":"Cummings SR, Schwatz AV, 2007 Alendronate and atrial fibrillation. N End J Med 356: 1895\u20131896.","journal-title":"N End J Med"},{"key":"8020096_CR77","doi-asserted-by":"publisher","first-page":"1799","DOI":"10.1056\/NEJMoa074941","volume":"357","author":"KW Lyles","year":"2007","unstructured":"Lyles KW, Colon-Emeric CS, Magaziner JS, et al, HORIZON Recurrent Fracture Trial, 2007 Zoledronic acid and clinical fractures and mortality after hip fracture. N Engl J Med 357: 1799\u20131809.","journal-title":"N Engl J Med"},{"key":"8020096_CR78","first-page":"712","volume":"356","author":"R Karam","year":"2007","unstructured":"Karam R, Camm J, McKlung M, 2007 Yearly zoledronic acid in postmenopausal osteoporosis. Letter. N Engl J Med 356: 712\u2013713.","journal-title":"Letter. N Engl J Med"},{"key":"8020096_CR79","doi-asserted-by":"publisher","first-page":"826","DOI":"10.1001\/archinte.168.8.826","volume":"168","author":"SR Heckhert","year":"2008","unstructured":"Heckhert SR, Li G, Cummings SR, et al, 2008 Use of alendronate and risk of incident atrial fibrillation in women. Arch Intern Med 168: 826\u2013831.","journal-title":"Arch Intern Med"},{"key":"8020096_CR80","doi-asserted-by":"publisher","first-page":"813","DOI":"10.1136\/bmj.39507.551644.BE","volume":"336","author":"HT Sorensen","year":"2008","unstructured":"Sorensen HT, Christensen S, Mehnert F, et al, 2008 Use of bisphosphonates among women and risk of atrial fibrillation and flutter: population based case-control study. BMJ 336: 813\u2013816.","journal-title":"BMJ"},{"key":"8020096_CR81","unstructured":"http:\/\/www.fda.gov.\/cder\/drug\/early_comm\/bisphosphonates_update_200811.htm"},{"key":"8020096_CR82","doi-asserted-by":"publisher","first-page":"1294","DOI":"10.1210\/jc.2004-0952","volume":"90","author":"CV Odvina","year":"2005","unstructured":"Odvina CV, Zerwekh JE, Rao ES, et al, 2005 Severely suppressed bone turnover: a potential complication of alendronate therapy. J Clin Endocrinol Metab 90: 1294\u20131301.","journal-title":"J Clin Endocrinol Metab"},{"key":"8020096_CR83","doi-asserted-by":"publisher","first-page":"2948","DOI":"10.1210\/jc.2007-2803","volume":"93","author":"M Visekruna","year":"2008","unstructured":"Visekruna M, Wilson D, McKienan FE, 2008 Severely suppressed bone turnover and atypical skeletal fragility. J Clin Endocrinol Metab 93: 2948\u20132952.","journal-title":"J Clin Endocrinol Metab"},{"key":"8020096_CR84","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1302\/0301-620X.89B3.18146","volume":"89","author":"SK Goh","year":"2007","unstructured":"Goh SK, Yang KY, Koh JS, et al, 2007 Subtrochanteric insufficiency fractures in patients on alendronate therapy: a caution. J Bone Joint Surg (Br) 89: 349\u2013353.","journal-title":"J Bone Joint Surg (Br)"},{"key":"8020096_CR85","doi-asserted-by":"publisher","first-page":"346","DOI":"10.1097\/BOT.0b013e318172841c","volume":"22","author":"AS Neviaser","year":"2008","unstructured":"Neviaser AS, Lane JM, Lenart BA, Edobor-Osula F, Lorich DG, 2008 Low-enrgy femoral shaft fractures associated with alendronate use. J Orthop Trauma 22: 346\u2013350.","journal-title":"J Orthop Trauma"},{"key":"8020096_CR86","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1016\/j.injury.2007.08.036","volume":"39","author":"EB Kwek","year":"2008","unstructured":"Kwek EB, Gosh SK, Koh JS, Png MA, Howe TS, 2008 An emerging pattern of subtrochanteric stress fractures: a long-term complication of alendronate therapy? Injury 39: 234\u2013231.","journal-title":"Injury"},{"key":"8020096_CR87","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1097\/00005373-199707000-00027","volume":"43","author":"S Salminen","year":"1997","unstructured":"Salminen S, Pihlajamaki H, Avikainen V, et al, 1997 Specific features associated with femoral shaft fractures caused by low-energy trauma. J Trauma 43: 117\u2013122.","journal-title":"J Trauma"},{"key":"8020096_CR88","first-page":"398","volume":"80","author":"P Kontoleon","year":"2000","unstructured":"Kontoleon P, Ilias I, Stavropoulos PG, Papapetrou PD, 2000 Urticaria after administration of alendronate. Acta Derm Venereol 80: 398.","journal-title":"Acta Derm Venereol"},{"issue":"4Pt","key":"8020096_CR89","doi-asserted-by":"publisher","first-page":"697","DOI":"10.1016\/S0091-6749(98)70291-X","volume":"102","author":"E Phillips","year":"1998","unstructured":"Phillips E, Knowles S, Weber E, Shear NH, 1998 Skin reactions associated with bisphosphonates: a report of 3 cases and an approach to management. Allergy Clin Immunol 102(4 Pt): 697\u2013698.","journal-title":"Allergy Clin Immunol"},{"key":"8020096_CR90","first-page":"233","volume":"6","author":"AD Anastasakis","year":"2007","unstructured":"Anastasakis AD, Goulis DG, Kita M, Avramidis A, 2007 Oral bisphosphonate adverse effects in 849 patients with metabolic bone disease. Hormones (Athens) 6: 233\u2013241.","journal-title":"Hormones (Athens)"},{"key":"8020096_CR91","first-page":"389","volume":"4","author":"A Lazarov","year":"2002","unstructured":"Lazarov A, Moss K, Plosk N, Cordova M, Baitelman L, 2002 Alendronate-induced lichen planus. IMAJ 4: 389\u2013390.","journal-title":"IMAJ"},{"key":"8020096_CR92","doi-asserted-by":"publisher","first-page":"945","DOI":"10.1067\/mjd.2003.245","volume":"48","author":"WA High","year":"2003","unstructured":"High WA, Cohen JB, Wetherington W, Cockerell CJ, 2003 Superficial gyrate erythema as a cutaneous reaction to alendronate for osteoporosis. J Am Acad Dermatol 48: 945\u2013946.","journal-title":"J Am Acad Dermatol"},{"key":"8020096_CR93","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1034\/j.1600-0536.2003.480212_2.x","volume":"48","author":"M Kimura","year":"2003","unstructured":"Kimura M, Kawada A, Murayama Y, Murayama M, 2003 Drug eruption due to alendronate sodium hydrate. Contact Dermatitis 48: 116.","journal-title":"Contact Dermatitis"},{"key":"8020096_CR94","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1111\/j.1600-0536.2006.01071.x","volume":"57","author":"T Brinkmeier","year":"2007","unstructured":"Brinkmeier T, K\u00fcgler K, Lepoittevin JP, Frosch PJ, 2007 Adverse cutaneous drug reaction to alendronate. Contact Dermatitis 57: 123\u2013125.","journal-title":"Contact Dermatitis"},{"key":"8020096_CR95","doi-asserted-by":"publisher","first-page":"1405","DOI":"10.1111\/j.1398-9995.2008.01836.x","volume":"63","author":"H Belhadjali","year":"2008","unstructured":"Belhadjali H, Slim R, Aouam K, Youssef M, Zilli J, 2008 Cutaneous vasculitis induced by risedronate. Allergy 63: 1405.","journal-title":"Allergy"},{"key":"8020096_CR96","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1007\/s100670050116","volume":"18","author":"N Demerjian","year":"2000","unstructured":"Demerjian N, Bolla G, Spreux A, 2000 Severe oral ulcerations induced by alendronate. Clin Rheumatol 18: 349\u2013350.","journal-title":"Clin Rheumatol"},{"key":"8020096_CR97","doi-asserted-by":"publisher","first-page":"514","DOI":"10.1034\/j.1600-0714.2000.291006.x","volume":"29","author":"MA Gonzalez-Moles","year":"2000","unstructured":"Gonzalez-Moles MA, Bagan-Sebastian JV, 2000 Alendronate-related oral mucosa ulcerations. J Oral Pathol Med 29: 514\u2013518.","journal-title":"J Oral Pathol Med"},{"key":"8020096_CR98","doi-asserted-by":"publisher","first-page":"651","DOI":"10.1016\/j.jaad.2003.07.030","volume":"50","author":"K Krasagakis","year":"2004","unstructured":"Krasagakis K, Kr\u00fcger-Krasagakis S, Ioannidou D, Tosca A, 2004 Chronic erosive and ulcerative oral lesions caused by incorrect administration of alendronate. J Am Acad Dermatol 50: 651\u2013652.","journal-title":"J Am Acad Dermatol"},{"key":"8020096_CR99","doi-asserted-by":"publisher","first-page":"930","DOI":"10.1016\/S0151-9638(05)79521-1","volume":"132","author":"JL Schmutz","year":"2005","unstructured":"Schmutz JL, Barbaud A, Trechot P, 2005 Alendronate et ulcerations buccales: d\u2019abord bien interroger le patient Ann Dermatol Venereol 132: 930.","journal-title":"Ann Dermatol Venereol"},{"key":"8020096_CR100","doi-asserted-by":"publisher","first-page":"e25","DOI":"10.1056\/NEJMicm054413","volume":"355","author":"P Rubegni","year":"2006","unstructured":"Rubegni P, Fimiani M, 2006 Images in clinical medicine. Bisphosphonate-associated contact stomatitis. N Engl J Med 355: e25.","journal-title":"N Engl J Med"},{"key":"8020096_CR101","first-page":"365","volume":"343","author":"A Halabe","year":"2000","unstructured":"Halabe A, Lifschitz BM, Azuri J, 2000 Liver damage due to alendronate 343: 365\u2013366.","journal-title":"Liver damage due to alendronate"},{"key":"8020096_CR102","first-page":"179","volume":"16","author":"C Carr\u00e9re","year":"2002","unstructured":"Carr\u00e9re C, Duvaal JL, Godard B, De Jaureguiberry JP, Ciribilli JM, 2002 Severe acute hepatitis induced by alendronate. Gastroenterol Clin Biol 16: 179\u2013180.","journal-title":"Gastroenterol Clin Biol"},{"key":"8020096_CR103","doi-asserted-by":"publisher","first-page":"829","DOI":"10.1007\/s00198-007-0323-2","volume":"18","author":"B Yanik","year":"2007","unstructured":"Yanik B, Turkay C, Atalar H, 2007 Hepatotoxicity induced by alendronate therapy. Osteoporos Int 18: 829\u2013831.","journal-title":"Osteoporos Int"},{"key":"8020096_CR104","doi-asserted-by":"publisher","first-page":"e1","DOI":"10.1016\/j.amjmed.2006.04.032","volume":"120","author":"MB Phillips","year":"2007","unstructured":"Phillips MB, 2007 Risedronate-induced hepatitis. Am J Med 120: e1\u20132.","journal-title":"Am J Med"},{"key":"8020096_CR105","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1056\/NEJMc0808738","volume":"360","author":"DK Wysowski","year":"2009","unstructured":"Wysowski DK, 2009 Reports of esophageal cancer with oral bisphosphonate use. N Engl J Med 360: 89\u201390.","journal-title":"N Engl J Med"},{"key":"8020096_CR106","volume-title":"Esophageal cancer in patients taking oral bisphosphonates","author":"Z Chustecka","year":"2009","unstructured":"Chustecka Z, 2009 Esophageal cancer in patients taking oral bisphosphonates. https:\/\/doi.org\/www.medscape.com\/view-article\/586127."}],"container-title":["Hormones"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.14310\/horm.2002.1226.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.14310\/horm.2002.1226\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.14310\/horm.2002.1226.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,9]],"date-time":"2025-02-09T15:34:19Z","timestamp":1739115259000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.14310\/horm.2002.1226"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,4]]},"references-count":106,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2009,4]]}},"alternative-id":["8020096"],"URL":"https:\/\/doi.org\/10.14310\/horm.2002.1226","relation":{},"ISSN":["1109-3099","2520-8721"],"issn-type":[{"value":"1109-3099","type":"print"},{"value":"2520-8721","type":"electronic"}],"subject":[],"published":{"date-parts":[[2009,4]]},"assertion":[{"value":"10 February 2009","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 March 2009","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 March 2009","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 April 2009","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This content has been made available to all.","name":"free","label":"Free to read"}]}}